Gulseren Pekbak

Gulseren Pekbak

Auto-generated profile, based on publicly available information

Gulseren Pekbak

Division of Immunology and Allergy, Department of Chest Diseases, Faculty of Medicine, Bursa Uludag University

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 May 2023 in Journal of Asthma
Verified
Journal Article
Closed access
GCGulfem Elif Celik
Gulfem Elif Celik
OAOmur Aydin
Omur Aydin
DGDerya Gökmen
Derya Gökmen
GBGozde Koycu Buhari
Gozde Koycu Buhari
ZSZeynep Celebi Sözener
Zeynep Celebi Sözener
AYArzu Yorgancioglu
Arzu Yorgancioglu
National data on asthma characteristics and the factors associated with uncontrolled asthma seem to be necessary for every country. For this purpose, we developed the Turkish Adult Asthma Registry ...

10 March 2023 in Tuberk Toraks
Verified
Journal Article
Open access
Dane EdigerDane Ediger
Dane Ediger
FGFatma Esra Gunaydin
Fatma Esra Gunaydin
MEMüge Erbay
Müge Erbay
GPGülseren Pekbak
Gülseren Pekbak
Omalizumab, a humanized monoclonal anti-IgE antibody, has largely demonstrated its efficacy in severe allergic asthma. There are limited data about the effectiveness of omalizumab in patients with non-atopic severe persistent asthma. In this study, we aimed to determine the effect of omalizumab in patients with non-atopic severe asthma and compare the data obtained with those in patients with allergic severe asthma. This study was an observational, retrospective, tertiary single-center study that assessed and compared the clinical outcome of adult patients with severe asthma (165 atopic and 41 non-atopic) who have been on omalizumab for one year or longer between January 2008 and January 2020. Effectiveness was assessed by considering symptom scores (GINA symptom control score), daily systemic corticosteroids (SCS) dosage, blood eosinophil counts, pulmonary function, and number of severe exacerbations and hospitalizations within the last one year. Omalizumab exhibited significant improvement in the clinical status of non-atopic asthma patients as measured by GINA symptom score [decreased from 3.77 ± 0.63 to 1.36 ± 1.27 (p<0.001)], the number of emergency room visits for asthma [decreased from 11.25 ± 14.69 to 0.25 ± 0.55 (p<0.001)], and the number of hospitalizations [decreased from 1.17 ± 2.87 to 0.14 ± 0.36 (p= 0.036)]. These results were not significantly different from those obtained in allergic asthma patients. FEV1 improved significantly from 2.08 ± 0.86 to 2.14 ± 0.84 (p= 0.041) and oral corticosteroid doses decreased significantly from 1.67 ± 7.49 to 0.46 ± 2.74 (p= 0.015) in the only atopic group. Omalizumab, which is a proven and effective treatment option for allergic asthma, may also be an efficacious alternative option in non-atopic severe asthma.

29 November 2024 in Respiratory Medicine
Verified
Journal Article
Closed access
BGBilun Gemicioglu
Bilun Gemicioglu
DGDerya Gökmen
Derya Gökmen
ACAli Can
Ali Can
CSCan Sevinc
Can Sevinc
IOI.Kivilcim Oguzulgen
I.Kivilcim Oguzulgen
GÇGülfem Elif Çelik
Gülfem Elif Çelik

15 May 2025 in Journal of Asthma
Verified
Journal Article
Closed access
SOSecil Kepil Ozdemir
Secil Kepil Ozdemir
BGBilun Gemicioglu
Bilun Gemicioglu
FYFusun Yildiz
Fusun Yildiz
SHSerhat HAYME
Serhat HAYME
GAGulistan Alpagat
Gulistan Alpagat
GCGulfem Elif Celik
Gulfem Elif Celik
Considerable overlaps exist between asthma phenotypes and the clinical significance of these overlaps remains undetermined. The objective of this study is to analyze the characteristics of asthma overlap phenotypes using data from the Turkish Adult Asthma Registry (TAAR). This cross-sectional registry study included 2053 adult patients (74.8% female) with asthma. Overall, 39.3% (n = 697) had allergic-eosinophilic (AE), 26.0% (n = 461) had allergic-non-eosinophilic (ANE), 21.3% (n = 377) had non-allergic-eosinophilic (NAE), and 13.4% (n = 237) had non-allergic-non-eosinophilic (NANE) asthma. Severe asthma exacerbations and emergency department (ED) visits were more frequent in the AE (28.3%, 31.2%, respectively) and NAE groups (36.0%, 34.0%, respectively) than in the ANE (14.3%, 20.6%, respectively) and NANE groups (12.6%, 16.7%, respectively) (p < 0.001). FEV1 values were significantly lower in the AE group than in the ANE and NANE groups (p < 0.001, p = 0.048, respectively) and in the NAE group than in the ANE group (p < 0.001). Risk factors for poor asthma control included living in rural areas, asthma-related ED visits, FEV1 < 60% in the NAE; being overweight, chronic rhinosinusitis, oral corticosteroids use, age < 40 years in the NANE; FEV1 < 80% in the AE; and severe asthma exacerbations, ED visits for AE and ANE groups. The considerable overlap between allergic and eosinophilic asthma phenotypes has clinical implications as increased rates of asthma exacerbations and healthcare utilization. The clinical heterogeneity among asthma phenotypes based on a single biomarker highlights the importance of multidimensional asthma phenotyping.

24 April 2025 in Bratislava Medical Journal
Verified
Journal Article
Open access
PDF file
DKDeniz Kızılırmak
Deniz Kızılırmak
OUOguz Uzun
Oguz Uzun
DGDerya Gökmen
Derya Gökmen
OAOmur Aydin
Omur Aydin
IBIlknur Basyigit
Ilknur Basyigit
GCGulfem Elif Celik
Gulfem Elif Celik
Objectives: It is aimed to assess how physicians use chest imaging in asthma and the relationship between the pathological findings and related disease characteristics in the radiological imaging of asthmatic patients. Background: The daily practice of imaging and its contribution to the management of asthma are not well defined. It is common to use radiological imaging to investigate pathologies that cause respiratory symptoms and to evaluate differential diagnoses in asthma patients. In this study, as a subanalysis of the Turkish Adult Asthma Registry, radiological findings and outcomes of asthmatic patients were examined. Methods: Between March 2018 and March 2022, the data of asthma patients in 36 secondary and tertiary health care centers was recorded using a web-based application. Patients with chest X-ray, computed thorax tomography, and paranasal sinus tomography data in the asthma database were statistically evaluated for sub-analysis. Results: The study included 2053 patients. Chest X-rays were taken in the majority of the cases (n:1739; 84.7%). Computed thorax tomography was performed in 869 (42.3%) patients and paranasal sinus tomography in 388 (18.9%) patients. The most common pathological findings on chest X-rays of asthmatic patients were increased bronchovascular branching and dirty lung appearance, whereas they were linear atelectasis, and bronchial wall thickening on computed thorax tomography bronchiectasis. Soft tissue in the sinuses and nasal polyps were the most common pathological findings in paranasal sinus tomography. Pathological findings were much more common in the radiological evaluations of patients with eosinophilic and allergic phenotypes and in patients with severe asthma. Conclusion: The radiological findings of asthma vary depending on the phenotype and severity of the disease. Patients with asthma, particularly those in the high-risk group, should be evaluated from a radiological perspective.

18 November 2026 in Journal of Asthma
Verified
Journal Article
Closed access
SISinem İnAn
Sinem İnAn
CSCan Sevinç
Can Sevinç
FAFunda Seher Özalp Ateş
Funda Seher Özalp Ateş
EÖEylem Sercan Özgür
Eylem Sercan Özgür
SBSerap Argun Baris
Serap Argun Baris
GÇGülfem Elif Çelik
Gülfem Elif Çelik